caa a22 4500 469026502 CHVBK 20180323132731.0 cr unu---uuuuu 170328e19920801xx s 000 0 eng 10.1007/BF01962533 doi (NATIONALLICENCE)springer-10.1007/BF01962533 Current status of interferon alpha in the treatment of chronic hepatitis B [Elektronische Daten] [J. Braken, P. Koopmans, I. Van Munster, F. Gribnau] Interferon alpha is the only available therapy for patients with chronic hepatitis B. With interferon alpha 3-15 MU thrice weekly or 5 MU daily during 3-6 months one-third of the patients achieve seroconversion of HBeAg and HBV-DNA together with normalization of aminotransferases and slight improvement of histology. Loss of HBsAg is reported in a minority of responders during treatment, but increases during follow-up. Patients with baseline alanine aminotransferase of at least twice the upper limit of normal and low HBV-DNA concentration achieve the best response rates. HIV-positive patients with low CD4 counts and Asians are poor responders. As side-effects influenza-like symptoms are experienced by almost all patients. Mild leukopenia, thrombocytopenia and decreased hairgrowth are frequently reported. Severe depression, depersonalization and psychosis are reported in a small number of patients but tend to be poorly recognized in some studies. The decision whether dose reduction is indicated seems strongly related to the opinion of the investigator. Although long-term effects on the occurrence of cirrhosis and the development of hepatocellular carcinoma are not available yet, the achieved results are promising. Royal Dutch Association for Advancement of Pharmacy, 1992 Clinical trials nationallicence Hepatitis B nationallicence Hepatitis B virus nationallicence Interferon type I nationallicence Pharmacokinetics nationallicence Prognosis nationallicence Side-effects nationallicence Braken J. Department of Pharmacology, Division of Pharmacology and Pharmacokinetics, Catholic University Nijmegen, P.O. Box 9101, 6500, HB Nijmegen, the Netherlands aut Koopmans P. Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, P.O. Box 9101, 6500, HB Nijmegen, the Netherlands aut Van Munster I. Department of Internal Medicine, Division of Gastroenterology and Hepatology, University Hospital Nijmegen, the Netherlands aut Gribnau F. Department of Pharmacology, Division of Pharmacology and Pharmacokinetics, Catholic University Nijmegen, P.O. Box 9101, 6500, HB Nijmegen, the Netherlands aut Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 167-173 0031-6911 14:4<167 1992 14 11096 https://doi.org/10.1007/BF01962533 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01962533 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Braken J. Department of Pharmacology, Division of Pharmacology and Pharmacokinetics, Catholic University Nijmegen, P.O. Box 9101, 6500, HB Nijmegen, the Netherlands aut NATIONALLICENCE 700 1- Koopmans P. Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, P.O. Box 9101, 6500, HB Nijmegen, the Netherlands aut NATIONALLICENCE 700 1- Van Munster I. Department of Internal Medicine, Division of Gastroenterology and Hepatology, University Hospital Nijmegen, the Netherlands aut NATIONALLICENCE 700 1- Gribnau F. Department of Pharmacology, Division of Pharmacology and Pharmacokinetics, Catholic University Nijmegen, P.O. Box 9101, 6500, HB Nijmegen, the Netherlands aut NATIONALLICENCE 773 0- Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 167-173 0031-6911 14:4<167 1992 14 11096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer